166 related articles for article (PubMed ID: 2839326)
1. Lisinopril: a new angiotensin-converting enzyme inhibitor.
Armayor GM; Lopez LM
Drug Intell Clin Pharm; 1988 May; 22(5):365-72. PubMed ID: 2839326
[TBL] [Abstract][Full Text] [Related]
2. Lisinopril: a new angiotensin-converting enzyme inhibitor.
Chase SL; Sutton JD
Pharmacotherapy; 1989; 9(3):120-8; discussion 128-30. PubMed ID: 2547199
[TBL] [Abstract][Full Text] [Related]
3. Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor.
Noble TA; Murray KM
Clin Pharm; 1988 Sep; 7(9):659-69. PubMed ID: 2853660
[TBL] [Abstract][Full Text] [Related]
4. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
Vlasses PH; Larijani GE; Conner DP; Ferguson RK
Clin Pharm; 1985; 4(1):27-40. PubMed ID: 2982541
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
Kubo SH; Cody RJ
Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
[TBL] [Abstract][Full Text] [Related]
6. The clinical pharmacology of lisinopril.
Case DE
J Hum Hypertens; 1989 Jun; 3 Suppl 1():127-31. PubMed ID: 2550635
[TBL] [Abstract][Full Text] [Related]
7. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Lancaster SG; Todd PA
Drugs; 1988 Jun; 35(6):646-69. PubMed ID: 2844497
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors: a comparative review.
Raia JJ; Barone JA; Byerly WG; Lacy CR
DICP; 1990 May; 24(5):506-25. PubMed ID: 2188439
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect.
Garavaglia GE; Messerli FH; Nunez BD; Schmieder RE; Frohlich ED
Am J Hypertens; 1988 Jul; 1(3 Pt 3):214S-216S. PubMed ID: 2843195
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group.
Giles TD; Katz R; Sullivan JM; Wolfson P; Haugland M; Kirlin P; Powers E; Rich S; Hackshaw B; Chiaramida A
J Am Coll Cardiol; 1989 May; 13(6):1240-7. PubMed ID: 2539403
[TBL] [Abstract][Full Text] [Related]
11. Enalapril: a new angiotensin converting enzyme inhibitor.
Cleary JD; Taylor JW
Drug Intell Clin Pharm; 1986 Mar; 20(3):177-86. PubMed ID: 3007062
[TBL] [Abstract][Full Text] [Related]
12. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor.
Giles TD; Fisher MB; Rush JE
Am J Med; 1988 Sep; 85(3B):44-7. PubMed ID: 2844087
[TBL] [Abstract][Full Text] [Related]
13. Lisinopril in the treatment of congestive heart failure.
Giles TD
J Hum Hypertens; 1989 Jun; 3 Suppl 1():83-7. PubMed ID: 2550647
[TBL] [Abstract][Full Text] [Related]
14. The safety and tolerability of lisinopril in clinical trials.
Rush JE; Merrill DD
J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S99-107. PubMed ID: 2442561
[TBL] [Abstract][Full Text] [Related]
15. The clinical pharmacology of lisinopril.
Gomez HJ; Cirillo VJ; Moncloa F
J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S27-34. PubMed ID: 2442549
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lisinopril and captopril in the treatment of left ventricular congestive heart failure--influence of duration of action on efficacy and safety.
Giles TD
Z Kardiol; 1991; 80 Suppl 2():35-9. PubMed ID: 1850941
[TBL] [Abstract][Full Text] [Related]
17. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man.
Semple PF; Cumming AM; Meredith PA; Morton JJ
Cardiovasc Drugs Ther; 1987; 1(1):45-50. PubMed ID: 2856460
[TBL] [Abstract][Full Text] [Related]
18. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
Langtry HD; Markham A
Drugs Aging; 1997 Feb; 10(2):131-66. PubMed ID: 9061270
[TBL] [Abstract][Full Text] [Related]
19. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
20. Duration of angiotensin-converting enzyme inhibition: implications for tolerability.
Murray NH
Cardiology; 1991; 79 Suppl 1():22-9. PubMed ID: 1655262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
